Predictors of glucocorticoid treatment intensity after endoscopic transsphenoidal surgery in patients with non-functional pituitary adenomas: a retrospective study - Takeaways - MDSpire

Factors Influencing Glucocorticoid Treatment Levels Following Endoscopic Transsphenoidal Surgery in Patients with Non-Functional Pituitary Adenomas: A Retrospective Analysis

  • By

  • Mengzhen Yu

  • Chen Wang

  • Yukui Li

  • Jinli Sun

  • Zhangyu Li

  • Janyao Mao

  • Wanting Qi

  • Ping Zhong

  • Sifang Chen

  • Guowei Tan

  • Wentao Zheng

  • Xi Chen

  • July 21, 2026

Share

  • 1

    Non-functioning pituitary adenomas (NFPAs) account for 22–54% of all pituitary tumors and can cause significant morbidity due to endocrine disturbances.

  • 2

    Endoscopic transsphenoidal surgery (eTSS) is the preferred treatment for NFPAs but often results in postoperative hypopituitarism and adrenal insufficiency.

  • 3

    Postoperative glucocorticoid therapy is necessary for many NFPA patients, yet optimal dosing remains a clinical challenge without standardized guidelines.

  • 4

    Independent predictors of glucocorticoid therapy intensity include tumor volume, suprasellar extension, pituitary stalk stretch, and preoperative morning cortisol levels.

  • 5

    The study developed a predictive model that explains 72.1% of the variance in glucocorticoid therapy intensity, aiding in individualized treatment strategies.

Original Source(s)

Related Content